Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Lyell Immunopharma Inc (NASDAQ: LYEL) closed at $1.09 down -5.22% from its previous closing price of $1.15. In other words, the price has decreased by -$5.22 from its previous closing price. On the day, 2.41 million shares were traded. LYEL stock price reached its highest trading level at $1.16 during the session, while it also had its lowest trading level at $1.085.
Ratios:
For a deeper understanding of Lyell Immunopharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.19 and its Current Ratio is at 16.19. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on June 27, 2024, Downgraded its rating to Neutral and sets its target price to $1 from $6 previously.
On August 28, 2023, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $15 to $5.
Morgan Stanley Downgraded its Overweight to Equal-Weight on November 14, 2022, whereas the target price for the stock was revised from $15 to $7.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 279043296 and an Enterprise Value of -151854608. For the stock, the TTM Price-to-Sale (P/S) ratio is 5580.80 while its Price-to-Book (P/B) ratio in mrq is 0.49. Its current Enterprise Value per Revenue stands at -2812.122 whereas that against EBITDA is 0.743.
Stock Price History:
Over the past 52 weeks, LYEL has reached a high of $3.26, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is -16.16%, while the 200-Day Moving Average is calculated to be -43.12%.
Shares Statistics:
For the past three months, LYEL has traded an average of 629.27K shares per day and 665610 over the past ten days. A total of 253.96M shares are outstanding, with a floating share count of 114.05M. Insiders hold about 55.45% of the company’s shares, while institutions hold 26.32% stake in the company. Shares short for LYEL as of 1727654400 were 10657278 with a Short Ratio of 16.94, compared to 1724976000 on 13764836. Therefore, it implies a Short% of Shares Outstanding of 10657278 and a Short% of Float of 5.91.
